Skip to main content

Advertisement

Table 1 Relationship between STAT3 promoter methylation, patient clinical characteristics and PA invasiveness

From: Signal transducer and activator of transcription 3 (STAT3) promoter methylation and expression in pituitary adenoma

  STAT3 gene methylation
Number of patients M (%) U (%) p-value
Cases 102 11(10.78) 91(89.22)  
Age (years)
  ≤ 60 40 4(10.00) 36(90.00) 0.837
  > 60 62 7(11.29) 55(88.71)
Gender
 Female 58 6(10.34) 52(89.66) 0.870
 Male 44 5(11.36) 39(88.64)
PA function
 Secreting 54 6(11.11) 48(88.89) 0.910
 Non-secreting 48 5(10.42) 43(89.58)
Relapse
 Appear 8 1(12.50) 7(87.50) 0.871
 None 94 10(10.64) 84(89.36)
Prolactinoma
 Appear 36 4(11.11) 32(88.89) 1.000
 None 18 2(11.11) 16(88.89)
Acromegaly
 Appear 9 1(11.11) 8(88.89) 1.000
 None 45 5(11.11) 40(88.89)
Cushing syndrome
 Appear 1 0(0.00) 1(100.00) 0.721
 None 53 6(11.32) 47(88.68)
Hormones
 PRL 36 4(11.11) 32(88.89)  
 IGF-1 2 0(0.00) 2(100.00)
 GH 4 2 (50.00) 2(50.00)
 ACTH 1 0(0.00) 1(100.00)
 Multiple 11 0(0.00) 11(100.00)
Invasiveness
 Invasive 58 7(12.07) 51(87.93) 0.428
 Non-invasive 30 2(6.67) 28(93.33)
  1. M methylated, U non-methylated, PRL prolactin, IGF-1 insulin-like grow factor 1, GH growth hormone, ACTH – adrenocorticotropic hormone, multiple – PAs secreting more than one hormone